MedTrace Logo

Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's Disease

NCT00559871 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2009-06-03

No results posted yet for this study

Summary

The purpose of this study is to determine whether Fipamezole is effective in the treatment of levodopa-induced dyskinesia in advanced Parkinson's disease.

Conditions

Interventions

DRUG

fipamezole

Fipamezole in Zydis formulation three times per day for up to 28 days

Sponsors & Collaborators

  • Santhera Pharmaceuticals

    collaborator INDUSTRY

  • Juvantia Pharma Ltd

    lead INDUSTRY

Principal Investigators

  • Peter A. LeWitt, M.D. · Henry Ford Health Systems, Franklin Pointe Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United States
  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00559871 on ClinicalTrials.gov